Expression of cytochrome P4502E1 in human liver: Assessment by mRNA, genotype and phenotype

Pharmacogenetics

Volumn 8, Issue 5, 1998, Pages 411-421

  Powell, H ^a   Kitteringham, N R ^a   Pirmohamed, M ^a   Smith, D A ^b   Park, B K ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Chlorzoxazone; CYP2E1; mRNA; P nitrophenol; RsaI polymorphism

Indexed keywords

ALCOHOL; CARCINOGEN; CHLORZOXAZONE; DIMETHYLNITROSAMINE DEMETHYLASE; MESSENGER RNA; NITROPHENOL; PROTOXIN; XENOBIOTIC AGENT;

ALLELE; ARTICLE; CARCINOGENICITY; CORRELATION FUNCTION; DNA FLANKING REGION; ENZYME ACTIVITY; ENZYME INDUCTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTRICTION FRAGMENT;

ADULT; AGED; CHLORZOXAZONE; CYTOCHROME P-450 CYP2E1; FEMALE; GENOTYPE; HUMANS; HYDROXYLATION; LIVER; MALE; MIDDLE AGED; NITROPHENOLS; PHENOTYPE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RNA, MESSENGER; TISSUE DONORS;

EID: 0031720001     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199810000-00006     Document Type: Article

References (45)

1. Carriere V, Berthou F, Baird S, Belloc C, Beaune P, Dewaziers I. Human cytochrome P4502E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics 1996; 6:203-211.
2. Gentile DM, Tomlinson ES, Maggs JL, Park BK, Back DJ. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exper Ther 1996; 277:105-112.
3. George J, Murray M, Byth K, Farrell GC. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 1995; 21:120-128.
4. George J, Byth K, Farrell GC. Influence of clinicopathological variables on CYP protein expression in human liver. J Gastroenterol Hepatol 1996; 11:33-39.
5. Gill HJ, Tingk MD, Park BK. N-hydroxylation of daprone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. BJ Clin Pharmacol 1995; 40:531-538.
6. Guengerich FP, Turvy CG. Comparison of levels of several human microsomal P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exper Ther 1991; 256:1189-1194.
7. Hakkola J, Pasanen M, Purkunen R, Saarikoski S, Pelkonen O, Maenpaa J, et al. Expression of xenobiotic-metabolising cytochrome P450 isoforms in human adult and foetal liver. Biochem Pharmacol 1994; 48:59-64.
8. Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem Tokyo 1991; 110:559-565.
9. Hildesheim A, Chen CJ, Caporaso NE, Cheng YJ, Hoover RN, Hsu MM, et al. Cytochrome P4502E1 genetic polymorphisms and risk of nasopharyngeal carcinoma - results from a case-control study conducted in Taiwan. Cancer Epidemiol Biomarkers Prev 1995; 4:607-610.
10. Hiroven A, Husgafvel-Pursianinen K, Anttila S, Karjalainen A, Vainio H. The human CYP2E1 gene and lung cancer: Dra I and Rsa I restriction length polymorphisms in a Finnish study population. Carcinogenesis 1993; 14:85-88.
11. Hu Y, Oscarson M, Johansson I, Yue QY, Dahl M-L, Taboue M, et al. Genetic polymorphisms of human CYP2E1: characterization of two variant alleles. Mol Pharmacol 1997; 51:370-376.
12. Ingelman-Sundberg M, Johansson I. Mechanisms of hydroxyl radical formation and ethanol oxidation by ethanol-inducible and other forms of rabbit liver microsomal cytochromes P-450. J Biol Chem 1984; 259:6447-6458.
13. Johansson I, Ingelman-Sundberg M. Carbon-tetrachloride-induced lipid peroxidation dependent on an ethanol-inducible form of rabbit liver microsomal cytochrome P-450. FEBS Lett 1985; 183:265-269.
14. Kato S, Shields PG, Caporaso NE, Hoover RN, Trump BF, Sugimura H, et al. Cytochrome P450IIE1 genetic polymorphisms, racial variation, and king cancer. Cancer Res 1992; 52:6712-6715.
15. Kato S, Onda M, Matsukura N, Tokunaga A, Tajiri T, Kim DY, et al. Cytochrome P4502E1 (CYP2E1) genetic-polymorphism in a case-control study of gastric-cancer and liver-disease. Pharmacogenetics 1995; 5:S141-S144.
16. Kim RB, O'Shea D, Wilkinson GR. Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the 6-hydroxylation of chlorzoxazone: a putative measure of CYP2E1 activity. Pharmacogenetics 1994; 4:162-165.
17. Kim RB, O'Shea D, Wilkinson GR. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 1995; 57:645-655.
18. Kim RB, Yamazaki H, Chiba K, O'Shea D, Mimura M, Guengerich FP, et al. In vivo and in vitro characterisation of CYP2E1 activity in Japanese and Caucasians. J Pharmacol Exper Ther 1996; 279:4-11.
19. Koop DR. Hydroxylation of p-nitrophenol by ethanol-inducible cytochrome P-450 isozyme 3a. Mol Pharmacol 1986; 29:399-404.
20. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-685.
21. Lasker JM, Rauey J, Kubota S, Bloswick BP, Black M, Lieber CS. Purification and characterization of human liver cytochrome P-450-ALC. Biochem Biophys Res Commun 1987; 148:232-238.
22. Lowry OH, Roseborough NJ, Farr AL, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem 1951; 193:265-275.
23. Lucas D, Menez C, Girre C, Berthou F, Bodenez P, Joannet I, et al. Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics 1995; 5:298-304.
24. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, et al. P450 superfamily: update of new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6:1-42.
25. Omura T, Sato R. The carbon monoxide binding pigment of liver microsomes. J Biol Chem 1964; 239:2370-2378.
26. O'Shea D, Davis SN, Kim RB, Wilkinson GR. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994; 56:359-367.
27. Oyama T, Kawamoto T, Mizoue T, Sugio K, Kodama Y, Mitsudomi T, Yasumoto K. Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Anticancer Res 1997; 17:583-587.
28. Peter R, Boecher R, Beaune PH, Inasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe of human liver cytochrome P-450IIE1. Chem Res Toxicol 1990; 3:566-573.
29. Pirmohamed M, Kitteringham NR, Quest LJ, Allott RL, Green VJ, Gilmore IT, Park BK. Genetic polymorphism of cytochrome P4502E1 and risk of alcoholic liver disease in Caucasians. Pharmacogenetics 1995; 5:351-357.
30. Ponte P, Ng SY, Engel J, Gunning P, Kedes L. Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA. Nucl Acids Res 1984; 12:1687-1696.
31. Ronis MJJ, Lindros KO, Ingelman-Sundberg M. The CYP2E subfamily. In: Ioannides C, editor. Cytochromes P450. Metabolic and toxicological aspects. Boca Raton: CRC Press: 1996, pp. 211-239.
32. Song BJ, Veech RL, Saenger P. Cytochrome P-450IIE1 is elevated in lymphocytes from poorly controlled insulin-dependent diabetics. J Clin Endocrinol Metab 1990; 71:1036-1040.
33. Takahashi T, Lasker JM, Rosman AS, Lieber CS. Induction of cytochrome P-4502E1 in the human liver by ethanol is caused by a corresponding increase in encoding messenger RNA. Hepatology 1993; 17:236-245.
34. Tassaneeyakul W, Veronese ME, Birkett DJ, Gonzalez FJ, Miners JO. Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem Pharmacol 1993; 46:1975-1981.
35. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1976; 76:4350-4354.
36. Tsutsumi M, Lasker JM, Takahashi T, Lieber CS. In vivo induction of hepatic P4502E1 by ethanol: role of increased enzyme synthesis. Arch Biochem Biophys 1993; 304:209-218.
37. Tsutsumi M, Wang J-S, Takada A. Hepatic messenger RNA contents of cytochrome P4502E1 in patients with different P4502E1 genotypes. Int Hepatol Commun 1994a; 2:135-138.
38. Tsutsumi M, Wang JS, Takada A. The influenceof CYP2E1 genotype on hepatic P4502E1 expression: possible implications in alcoholic liver disease. Hepatology 1994b; 19, 1135.
39. Ueshima Y, Tsutsumi M, Takase S, Matsuda Y, Kawahara H. Acetaminophen metabolism in patients with different P-4502E1 genotypes. Alcohol Clin Exp Res 1996; 20:25A-28A.
40. Watanabe J, Hayashi S, Nakachi K, Imai K, Suda Y, Sekine T, Kawajiri K. PstI and RsaI RFLPs in complete linkage disequilibrium at the CYP2E gene. Nucleic Acids Res 1990 18:7194.
41. Watanabe J, Hayashi S, Kawajiri K. Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5′-flanking region. J Biochem 1994; 116:321-326.
42. Watanabe J, Yang JP, Eguchi H, Hayashi S, Imai K, Nakachi K, Kawajiri K. An Rsa I polymorphism in the CYP2E1 gene does not affect lung cancer risk in a Japanese population. Jap J Cancer Res 1995; 86:245-248.
43. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996; 111:1645-1653.
44. Wu X, Shi H, Jiang H, Kemp B, Hong WK, Delclos GL, Spitz MR. Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis 1997; 18:967-975.
45. Yang CS, Yoo JS, Ishizaki H, Hong J. Cytochrome P450IIE1: roles of nitrosamine metabolism and mechanisms of regulation. Drug Metab Rev 1990; 22:147-159.